Rhea Celecoxib

Rhea Celecoxib

celecoxib

Manufacturer:

Pfizer

Distributor:

Philusa
Concise Prescribing Info
Contents
Celecoxib
Indications/Uses
Symptomatic treatment of OA & RA; relief of signs & symptoms of ankylosing spondylitis; management of acute pain; treatment of primary dysmenorrhea; acute & chronic low back pain.
Dosage/Direction for Use
Adult Symptomatic treatment of OA, ankylosing spondylitis 200 mg as single dose or 100 mg bid. Symptomatic treatment of RA 100 or 200 mg bid. Management of acute pain Initially 400 mg followed by 200 mg on the 1st day & 200 mg bid or 400 mg once daily subsequently. Treatment of primary dysmenorrhea Initially 400 mg followed by 200 mg on the 1st day & 200 mg bid subsequently.
Administration
May be taken with or without food: Dose of OA/RA may be given w/ or w/o meals.
Contraindications
Hypersensitivity to celecoxib or sulfonamides. Patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or NSAIDs including COX-2 inhibitors. Treatment of peri-operative pain in the setting of CABG.
Special Precautions
Patients w/ ischemic heart disease & those at risk of heart disease, HTN, hyperlipidemia, diabetes, smoking; peripheral arterial disease. Risk of CV, GI, renal & hepatic effects; fluid retention & edema; anaphylactoid & serious skin reactions. Concomitant use w/ warfarin or similar agents; non-aspirin NSAID. May diminish utility of diagnostic signs eg, fever in detecting infections. Not a substitute for aspirin in the prophylactic treatment of CV disease. Pregnancy & lactation.
Adverse Reactions
Bronchitis, sinusitis, upper resp tract infection, UTI; insomnia; dizziness; HTN (including aggravated HTN); cough; vomiting, abdominal pain, diarrhea, dyspepsia, flatulence; pruritus (including generalized pruritus), rash; peripheral edema.
Drug Interactions
Drugs metabolized by CYP2D6. Serious bleeding events w/ warfarin or similar agents. Increased lithium plasma levels. Diminished antihypertensive effects of ACE inhibitors &/or AIIA. Increased risk of nephrotoxicity w/ cyclosporine. Increased plasma conc w/ CYP2C9 inhibitors, fluconazole & ketoconazole. Increase plasma conc of dextromethorphan & metoprolol. Reduced natriuretic effects of furosemide & thiazides.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AH01 - celecoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.
Presentation/Packing
Form
Rhea Celecoxib cap 200 mg
Packing/Price
60's (P1,410/box)
Form
Rhea Celecoxib cap 400 mg
Packing/Price
60's (P2,670/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in